Discover how the first-in-class DOT1L PROTAC degrader MS2133 could revolutionize treatment for MLL-rearranged leukemia by completely eliminating the cancer-causing protein.
Exploring how VHL protein dysfunction drives kidney cancer and the innovative therapies targeting this pathway.